Company Overview and News
Shares of Kellogg Company (K - Free Report) touched a 52-week high of $74.91, before closing the session a tad lower at $74.84 on Sep 14. Clearly, the company has been benefiting from the RXBAR and Pringles buyouts, and the consolidation of Multipro. It is on-track with savings initiatives as well. Backed by such efforts, Kellogg delivered solid second-quarter 2018 results, wherein top and bottom line not only surpassed the Zacks Consensus Estimate but also improved on year-over-year basis.
STQN MED PF CHEF
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN MA CVS BRK.A KMI ABBV OXY KMR KMRFZ CVB ABBV
On Aug 20, shares of Becton, Dickinson and Company (BDX - Free Report) , also known as BD, reached a 52-week high of $254.35, closing the session marginally lower at $252.81. The stock rallied to the high following impressive third-quarter fiscal 2018 results released earlier this month.
MASI STQN MLNX ISRG
On Aug 13, we issued an updated research report on Crown Holdings, Inc. (CCK - Free Report) . The company is poised to gain from geographic expansion, acquisitions and focus on capital allocation. Its Transit Packaging business also remains a growth driver. Nevertheless, elevated freight costs, foreign currency-translation impact and raw-material inflation might impede the company’s near-term growth.
ROP STQN CCK AIT GTLS
Fortive Corporation (FTV - Free Report) is set to report second-quarter 2018 results on Jul 26. The company topped the Zacks Consensus Estimate in the trailing four quarters, recording an average beat of 4.73%. In the last reported quarter, Fortive delivered a positive earnings surprise of 5.41%. Earnings of 78 cents per share surged 30% year over year but declined 4.9% sequentially. The figure also came ahead of management’s guidance of 72-76 cents.
LMT FTV AEIS A STQN AME
Key players and manufacturers are increasingly focusing on expansion and acquisition, for the purpose of enhancing their functional effectiveness as well as product portfolio. Apart from this, joint ventures and strategic collaborations are likely to improve the production sales of electric and hydraulic wellhead drive for the onshore application in the forthcoming years.
PayPal Holdings, Inc. (PYPL - Free Report) is set to report second-quarter 2018 results on Jul 25. The company topped the Zacks Consensus Estimate in the trailing four quarters, delivering an average positive earnings surprise of 6.35%. In the last reported quarter, PayPal’s earnings of 57 cents per share grew 29.5% on a year-over-year basis and 3.6% sequentially. The figure also surpassed the Zacks Consensus Estimate by 3 cents.
83SF FB BCS OIL 83SK KDP STQN TWTR AAPL PYPL 47MC
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike (NKE), Morgan Stanley (MS) and FedEx (FDX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HD UPS STQN FDX ELLI MT NKE IR SPG MS MT
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), NVIDIA (NVDA) and Danaher (DHR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN ADP MA NVDA BRK.A ADPVV ICE GM OXY DHR MODN
Frutarom Expects 2018 to be Yet Another Record Year, as it Continues to Improve its Profitability, also through Projects for Combining Plants and Resource Optimization, and the Successful Completion of the Enzymotec Acquisition
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET